CD86 and neoplasm: To study the immune status underlying the resistance to tumor rechallenge in the above mice, 15 d after rechallenging, we observed the enhanced expression of CD40 (Figure 7D), CD86 (Figure 7E), and MHC‐II (Figure 7F) on DCs from PBMCs of “APHP‐CCCA+808+660” group.